The 22 patients with hematological malignancies who underwent an HLA-matched related or unrelated alloHSCT from September 2021 to May 2021 at our institution were considered eligible to receive the modified institutional transplant protocol composed by reduced doses of PTCY and tacrolimus and G-CSF from day +7 to neutrophil recovery and included in this study. This evidence concerns the gene CSF3 and hematologic disorder.